Evidence map›Paper›PMID 29110283›Full record

ArticlePharmaceutical research2017

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

Fateme Haghiralsadat, Ghasem Amoabediny, Samira Naderinezhad, Kamran Nazmi, Jantine Posthuma De Boer, Behrouz Zandieh-Doulabi, Tymour Forouzanfar, Marco N Helder

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Fateme HaghiralsadatDepartment of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran.
Ghasem AmoabedinyDepartment of Biotechnology and Pharmaceutical Engineering, Faculty of Chemical Engineering, School of Engineering, University of Tehran, Tehran, Iran. amoabedini@ut.ac.ir.
Samira NaderinezhadDepartment of Biotechnology and Pharmaceutical Engineering, Faculty of Chemical Engineering, School of Engineering, University of Tehran, Tehran, Iran.
Kamran NazmiDepartment of Oral Biochemistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Univrsiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Jantine Posthuma De BoerDepartment of Orthopedic Surgery, VU University Medical Center, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Behrouz Zandieh-DoulabiOral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Tymour ForouzanfarDepartment of Oral & Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, Amsterdam, The Netherlands.
Marco N HelderDepartment of Oral & Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, Amsterdam, The Netherlands.
Amsterdam UMC Location VUmc · NLUniversity of Tehran · IRAcademic Center for Dentistry Amsterdam · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo employ Doxorubicin-loaded liposomes, modified with YSA-peptide to target EphA2, to reduce adverse effects against primary bone cells and maximize toxicity against Saos-2 osteosarcoma cells.

methodsPEGylated liposomes were prepared by thin film method using Dipalmitoylphosphatidylcholine (DPPC), cholesterol and distearylphosphatidylethanolamine-polyethyleneglycol conjugate (DSPE-mPEG) in 67.9:29.1:3 M ratios, and loaded with DOX (L-DOX) by pH-gradient method. Targeted liposomes (YSA-L-DOX), were prepared by conjugating YSA-peptide to DSPE-mPEG. Liposomes were physicochemically characterized and tested in cellular toxicity assays.

resultsYSA conjugation efficiency was >98%. Size and polydispersity index of both L-DOX and YSA-L-DOX were around 88 nm and 0.188, respectively. Both had similar zeta potential, and 85% DOX loading efficiencies. DOX release kinetics followed the Korsmeyer-Peppa model, and showed comparable release for both formulations from 1-8 h, and a plateau of 29% after 48 h. Both formulations could be stably stored for ≥6 months at 4°C in the dark. Toxicity assays showed a significant 1.91-fold higher cytotoxicity compared to free DOX in the Saos-2 cells, and 2-fold lesser toxicity in primary bone cells compared to the Saos-2 cells. Cellular uptake studies showed higher and more nuclear uptake in YSA-L-DOX compared to L-DOX treated cells.

conclusionsYSA-L-DOX vesicles might be effective for targeted treatment of osteosarcoma.

Indexed as

Drug Delivery SystemsAntibiotics, AntineoplasticBone NeoplasmsCell Line, TumorDoxorubicinHumansLiposomesOsteosarcomaPeptidesPolyethylene GlycolsReceptor, EphA2Antibiotics, AntineoplasticDoxorubicinliposomal doxorubicinLiposomesPeptidesPolyethylene GlycolsReceptor, EphA2liposomeosteosarcoma targetingYSA peptide

Identifiers

PMID29110283
OpenAlexW2767892582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.